Pall Corp. has entered a strategic collaboration with Artesyn Biosolutions, a company specializing in single-use components and fluid management technologies. The agreement will encompass a co-development partnership, delivering complete solutions from clinical to commercial-scale for single-use automated bioprocessing systems. These systems aim to enable the industry to accelerate product development and time to market through a fully industrialized and standard platform for cGMP manufacturing of biotech and biological products.

The partnership expands Pall Biotech’s Allegro single-use solution portfolio from upstream through downstream, and to final filling. The strategic collaboration aims to provide industrial and modular single-use bioprocess solutions, resulting in robust fluid management.

Mario Philips, vice president and general manager, Pall Biotech, said, “This partnership reflects Pall’s pursuit of innovative earlier stage companies as a way to access advanced technologies. Our vision aligns with industry expectations to enable single-use technologies to reach the status of a fully industrialized solution. With the Artesyn Biosolutions valves and fluid handling technologies, the Pall Allegro solutions, such as the Allegro STR bioreactors, and range of downstream automated equipment and mixers will enable our customers to implement efficient single-use manufacturing lines.”

Michael Gagne, Artesyn Biosolutions’ founder and CEO, said, “Our mission at Artesyn Biosolutions is to accelerate the accessibility and capabilities of single-use technologies that increase the availability of life saving drugs.  We are excited to be working with Pall Biotech and their innovative team of professionals to develop a suite of solutions that enable abundance in medicine.”